MERCANS
ISG, an independent research firm, has recognized Mercans as a Leader in its exclusive Global Managed Payroll Services (Multi-Country) ISG Provider Lens™ 2023 report. Among 36 Payroll Solutions and Services vendors assessed comprehensively, Mercans emerged as a clear industry leader. This prestigious acknowledgment by a leading analyst firm solidifies Mercans’ position as a technology leader in the payroll industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211410383/en/
Mercans Achieves Leadership Status in Global Managed Payroll Services - ISG Provider Lens™ 2023 (Photo: AETOSWire)
ISG praised Mercans for its Digital Transformation in Streamlined Payroll. Mercans’ single platform gross-to-net payroll engine is revolutionary and has disrupted the global payroll industry. Its G2N Nova is the only stateless global payroll application that enables generating gross-to-net payroll calculations across 100+ countries in seconds and without storing any employee data. This disruptive and innovative approach to global payroll has become the pathway for multinationals to fully digitalize their global payroll operations. In addition to being the only global gross-to-net payroll application, G2N Nova delivers completely autonomous and touchless payroll experience, drastically reducing payroll processing times and costs.
Mercans’ proprietary payroll technology has changed the traditional aggregation and manual processes based global payroll model by eliminating the need for in-country subcontractors and third-party software solutions. Mercans’ payroll platform can be seamlessly integrated with any HR software and allows electronic generation and submission of statutory reports across the globe. G2N Nova cutting-edge horizontal architecture makes it possible to consolidate payroll processing and reporting on a single software that powers SaaS and managed payroll services across thousands of companies and more than 100 countries.
Mercans CEO of Payroll & SaaS, Vishwanathan Arunachalam (Vish), emphasized, “This recognition underscores our comprehensive product and service offerings, robust market presence, and enduring competitive position. We are committed to innovative practices and competitive stability.”
Strengths commended by ISG for Mercans:
- Streamlined, Efficient Processing
- Tailored Service Packages
- Technological Prowess
- Global Expertise
Rachel Anderson, Lead Analyst at ISG, commends Mercans, stating, “Mercans is a global leader in payroll technology and services. Its proprietary HR Blizz global payroll infrastructure, coupled with native calculation engines, serves the requirements of 160 countries with remarkable finesse.”
This distinction showcases Mercans' dedication to innovation and excellence in Global Payroll Services, setting a high standard for the industry's future.
Read the full ISG Provider Lens™ 2023 report here.
About Mercans
Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll platform HR Blizz enables SMBs & Enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.
Visit www.mercans.com
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231211410383/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom